Xenon Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Xenon Pharmaceuticals generated cash of -$145,327,000, which is less than the previous year. Cash used in financing activities reached the amount of $353,522,000 last year. Net change in cash is therefore $91,401,000.
Cash Flow
| 2014 | 266K | -3.24M | 41.12M |
|---|---|---|---|
| 2015 | -18.10M | 10.19M | 278K |
| 2016 | -19.56M | -47.84M | 23.96M |
| 2017 | -28.72M | 24.29M | 7.07M |
| 2018 | -34.72M | -28.98M | 111.59M |
| 2019 | -4.63M | -66.29M | 27.51M |
| 2020 | -48.12M | -16.82M | 85.79M |
| 2021 | -69.50M | -246.77M | 447.54M |
| 2022 | -98.43M | -296.00M | 278.47M |
| 2023 | -145.32M | -117.17M | 353.52M |
XENE Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 57.24M | 175.68M | 45.00M | 24.75M | 67.75M | 20.48M | 17.09M | 58.65M | 72.02M | 37.95M |
Operating activities | ||||||||||
Net income | -182.39M | -125.37M | -78.88M | -28.83M | -41.59M | -34.49M | -30.70M | -22.99M | -15.75M | 13.01M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 3.54M | 1.62M | 906K | 644K | 429K | 586K | 649K | 864K | 1.03M | 738K |
Stock-based compensation expense | 32.37M | 20.37M | 10.01M | 5.67M | 2.92M | 0 | 2.23M | 2.16M | 3.72M | 760K |
| Deferred income tax benefit | 32.37M | 20.37M | 10.01M | 5.67M | 2.92M | 0 | 2.23M | 2.16M | 3.72M | 760K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 130K | 1.75M | -459K | -1.03M | -653K | 175K | -232K | 121K | -107K | 209K |
Inventories | 0 | 0 | -2.97M | -2.02M | -4.54M | -783K | 613K | 571K | 0 | -573K |
Accounts payable | 3.93M | 8.06M | 2.97M | 2.02M | 4.54M | 783K | -3K | 547K | 80K | 518K |
Cash generated by operating activities | -145.32M | -98.43M | -69.50M | -48.12M | -4.63M | -34.72M | -28.72M | -19.56M | -18.10M | 266K |
Investing activities | ||||||||||
Purchases Of Investments | -793.90M | -551.13M | -389.47M | -228.89M | -140.49M | -77.00M | -28.00M | -47.56M | 0 | -15.25M |
Investments In Property Plant And Equipment | -5.61M | -2.89M | -2.05M | -2.63M | -1.24M | -507K | -315K | -279K | -551K | -1.52M |
Acquisitions Net | 0 | 296.00M | -144.75M | -214.71M | -75.44M | -48.52M | -52.61M | 0 | 0 | -13.53M |
Cash generated by investing activities | -117.17M | -296.00M | -246.77M | -16.82M | -66.29M | -28.98M | 24.29M | -47.84M | 10.19M | -3.24M |
Financing activities | ||||||||||
Common Stock Issued | 353.48M | 277.76M | 447.28M | 102.45M | 27.39M | 102.85M | 177K | 0 | 278K | 42.65M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -16.74M | 0 | -8.45M | 6.89M | 0 | 0 | 0 |
Cash used in financing activities | 353.52M | 278.47M | 447.54M | 85.79M | 27.51M | 111.59M | 7.07M | 23.96M | 278K | 41.12M |
Net Change In Cash | 91.40M | -118.44M | 130.67M | 20.25M | -42.99M | 47.26M | 3.39M | -41.55M | -13.37M | 34.07M |
Cash at end of period | 148.64M | 57.24M | 175.68M | 45.00M | 24.75M | 67.75M | 20.48M | 17.09M | 58.65M | 72.02M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |